Monte Rosa Therapeutics

Monte Rosa Therapeutics Revenue

The The revenue of Monte Rosa Therapeutics (GLUE) as of Nov 22, 2026 is 123.67 M USD. In the previous year, The revenue was 75.62 M USD — a change of 63.54% (higher).

Revenue

123.67 MUSD

YoY

63.54%

Last updated:

In 2025, Monte Rosa Therapeutics's sales reached 123.67 M USD, a 63.54% difference from the 75.62 M USD sales recorded in the previous year.

The Monte Rosa Therapeutics Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2023
0.00 USD
Jan 1, 2024
75.62 M USD
Jan 1, 2025
123.67 M USD
Jan 1, 2026 (e)
103.14 M USD
Jan 1, 2027 (e)
62.13 M USD
Jan 1, 2028 (e)
120.83 M USD
Jan 1, 2029 (e)
116.07 M USD
Jan 1, 2030 (e)
138.77 M USD
The Monte Rosa Therapeutics Revenue history
YEARRevenueYoY
est138.77 MUSD+19.55%
est116.07 MUSD-3.94%
est120.83 MUSD+94.47%
est62.13 MUSD-39.76%
est103.14 MUSD-16.60%
123.67 MUSD+63.54%
75.62 MUSD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Monte Rosa Therapeutics Revenue

Monte Rosa Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-143.31 M USD
-135.35 M USD
Jan 1, 2024
75.62 M USD
-81.11 M USD
-72.70 M USD
Jan 1, 2025
123.67 M USD
-54.21 M USD
-38.63 M USD
Jan 1, 2026 (e)
103.14 M USD
-57.83 M USD
-76.55 M USD
Jan 1, 2027 (e)
62.13 M USD
-75.24 M USD
-131.60 M USD
Jan 1, 2028 (e)
120.83 M USD
-159.86 M USD
-118.66 M USD
Jan 1, 2029 (e)
116.07 M USD
-146.95 M USD
-163.49 M USD
Jan 1, 2030 (e)
138.77 M USD
-142.89 M USD
-158.97 M USD

Monte Rosa Therapeutics Margins

Monte Rosa Therapeutics stock margins

The Monte Rosa Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Monte Rosa Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Monte Rosa Therapeutics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
93.24 %
- %
- %
Jan 1, 2024
89.26 %
-107.26 %
-96.14 %
Jan 1, 2025
93.24 %
-43.83 %
-31.23 %
Jan 1, 2026 (e)
93.24 %
-56.07 %
-74.22 %
Jan 1, 2027 (e)
93.24 %
-121.09 %
-211.80 %
Jan 1, 2028 (e)
93.24 %
-132.30 %
-98.20 %
Jan 1, 2029 (e)
93.24 %
-126.60 %
-140.85 %
Jan 1, 2030 (e)
93.24 %
-102.97 %
-114.56 %

Monte Rosa Therapeutics Stock analysis

What does Monte Rosa Therapeutics do? Monte Rosa Therapeutics, Inc. develops precision medicines using molecular glue degraders (MGDs), small molecule drugs that harness the body's protein destruction mechanisms. The company's QuEEN platform enables target-centric MGD discovery, supporting its development of MRT-2359, an orally bioavailable MGD targeting GSPT1 for MYC-driven tumors like metastatic non-small cell lung cancer and small cell lung cancer. Clinical development focuses on oncology applications, leveraging biological and genetic rationale for novel therapies. The firm targets oncology segments with MGD-based treatments for specific cancer types. MRT-2359 is the primary product candidate in clinical development, designed to degrade GSPT1 in tumors driven by MYC overexpression. The company's approach centers on rational design of MGDs using its QuEEN platform, aiming to address unmet needs in oncology. Therapeutic applications include metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors, where current treatment options are limited. The focus remains on developing targeted therapies for these specific cancer segments. The company's revenue model relies on advancing MRT-2359 through clinical trials toward regulatory approval. Once approved, it would commercialize MRT-2359 for oncology indications, generating revenue from pharmaceutical sales. The target market includes patients with MYC-driven tumors requiring new treatment options, with potential partnerships for co-development or licensing as the drug progresses. Clinical development stages determine the next phase of revenue generation, with no current products on the market. Monte Rosa Therapeutics is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Monte Rosa Therapeutics's Sales Figures

The sales figures of Monte Rosa Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Monte Rosa Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Monte Rosa Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Monte Rosa Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Monte Rosa Therapeutics stock

The revenue of Monte Rosa Therapeutics is 123.67 M USD in 2025.

The revenue of Monte Rosa Therapeutics changed from 75.62 M USD to 123.67 M USD, representing a 63.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Monte Rosa Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Monte Rosa Therapeutics historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Monte Rosa Therapeutics

All Key Metrics — Monte Rosa Therapeutics